Evidence map›Paper›PMID 30721409›Full record

ArticleActa neuropathologica2019

Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo.

Ilie-Cosmin Stancu, Niels Cremers, Hannah Vanrusselt, Julien Couturier, Alexandre Vanoosthuyse, Sofie Kessels, Chritica Lodder, Bert Brône, François Huaux, Jean-Noël Octave and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
266citing papers in PubMed, 3 pooled it
24.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

266 citing papers in PubMed, 3 syntheses or guidelines pooled it, 437 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Fraxetin Ameliorates Cognitive Impairment in STZ-Induced Mice: Involvement of Suppressed Microglial Hyperactivation and Improved Mitochondrial Dysfunction.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Neuroinflammation and Tauopathies.Molecular biology reports · 2026
    Review
  15. Article
  16. Article
  17. Review
  18. Immune signaling and function in neurodegeneration.The Journal of clinical investigation · 2026
    Review
  19. Review
  20. Article

206 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ilie-Cosmin StancuBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Niels CremersBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Hannah VanrusseltBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Julien CouturierAlzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.
Alexandre VanoosthuyseAlzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.
Sofie KesselsBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Chritica LodderBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Bert BrôneBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
François HuauxLouvain Center for Toxicology and Applied Pharmacology, Catholic University of Louvain, 1200, Brussels, Belgium.
Jean-Noël OctaveAlzheimer Dementia Group, Institute of Neuroscience, Catholic University of Louvain, 1200, Brussels, Belgium.
Dick TerwelBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium.
Ilse DewachterBiomedical Research Institute, Hasselt University, 3500, Hasselt, Belgium. ilse.dewachter@uhasselt.be.
Hasselt University · BEUCLouvain · BE

Funding

Agentschap Innoveren en Ondernemen VLAIOFondation pour la Recherche Alzheimer (FRA-SAO-Belgium) FRA-SAO BelgiumFonds Wetenschappelijk Onderzoek G0C6819N
6 · The paper itself

Abstract

Brains of Alzheimer's disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, both invariably associated with neuroinflammation. A crucial role for NLRP3-ASC inflammasome [NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-Apoptosis-associated speck-like protein containing a CARD (ASC)] in amyloid-beta (Aβ)-induced microgliosis and Aβ pathology has been unequivocally identified. Aβ aggregates activate NLRP3-ASC inflammasome (Halle et al. in Nat Immunol 9:857-865, 2008) and conversely NLRP3-ASC inflammasome activation exacerbates amyloid pathology in vivo (Heneka et al. in Nature 493:674-678, 2013), including by prion-like ASC-speck cross-seeding (Venegas et al. in Nature 552:355-361, 2017). However, the link between inflammasome activation, as crucial sensor of innate immunity, and Tau remains unexplored. Here, we analyzed whether Tau aggregates acting as prion-like Tau seeds can activate NLRP3-ASC inflammasome. We demonstrate that Tau seeds activate NLRP3-ASC-dependent inflammasome in primary microglia, following microglial uptake and lysosomal sorting of Tau seeds. Next, we analyzed the role of inflammasome activation in prion-like or templated seeding of Tau pathology and found significant inhibition of exogenously seeded Tau pathology by ASC deficiency in Tau transgenic mice. We furthermore demonstrate that chronic intracerebral administration of the NLRP3 inhibitor, MCC950, inhibits exogenously seeded Tau pathology. Finally, ASC deficiency also decreased non-exogenously seeded Tau pathology in Tau transgenic mice. Overall our findings demonstrate that Tau-seeding competent, aggregated Tau activates the ASC inflammasome through the NLRP3-ASC axis, and we demonstrate an exacerbating role of the NLRP3-ASC axis on exogenously and non-exogenously seeded Tau pathology in Tau mice in vivo. The NLRP3-ASC inflammasome, which is an important sensor of innate immunity and intensively explored for its role in health and disease, hence presents as an interesting therapeutic approach to target three crucial pathogenetic processes in AD, including prion-like seeding of Tau pathology, Aβ pathology and neuroinflammation.

Indexed as

Alzheimer DiseaseAnimalsBrainCARD Signaling Adaptor ProteinsGliosisInflammasomesInterleukin-1betaMiceMice, TransgenicMicrogliaNLR Family, Pyrin Domain-Containing 3 ProteinProtein Aggregatestau ProteinsCARD Signaling Adaptor ProteinsInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinProtein AggregatesPycard protein, mousetau ProteinsAD and TauopathiesInflammationIn vivo modelsPropagation of Tau pathologyTauTau pathology

Identifiers

PMID30721409
PMCPMC6426830
OpenAlexW2912579052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.